The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer
AuthorsAlexander, P. G.
Roseweir, A. K.
Pennel, K. A. F.
van Wyk, H. C.
McMillan, D. C.
Horgan, P. G.
Roxburgh, C. S. D.
Church, D. N.
Saunders, Mark P
Iveson, T. J.
Park, J. H.
AffiliationSchool of Medicine, University of Glasgow, Glasgow, UK
MetadataShow full item record
AbstractBackground: The Glasgow Microenvironment Score (GMS) combines peritumoural inflammation and tumour stroma percentage to assess interactions between tumour and microenvironment. This was previously demonstrated to associate with colorectal cancer (CRC) prognosis, and now requires validation and assessment of interactions with adjuvant therapy. Methods: Two cohorts were utilised; 862 TNM I-III CRC validation cohort, and 2912 TNM II-III CRC adjuvant chemotherapy cohort (TransSCOT). Primary endpoints were disease-free survival (DFS) and relapse-free survival (RFS). Exploratory endpoint was adjuvant chemotherapy interaction. Results: GMS independently associated with DFS (p = 0.001) and RFS (p < 0.001). GMS significantly stratified RFS for both low risk (GMS 0 v GMS 2: HR 3.24 95% CI 1.85-5.68, p < 0.001) and high-risk disease (GMS 0 v GMS 2: HR 2.18 95% CI 1.39-3.41, p = 0.001). In TransSCOT, chemotherapy type (pinteraction = 0.013), but not duration (p = 0.64) was dependent on GMS. Furthermore, GMS 0 significantly associated with improved DFS in patients receiving FOLFOX compared with CAPOX (HR 2.23 95% CI 1.19-4.16, p = 0.012). Conclusions: This study validates the GMS as a prognostic tool for patients with stage I-III colorectal cancer, independent of TNM, with the ability to stratify both low- and high-risk disease. Furthermore, GMS 0 could be employed to identify a subset of patients that benefit from FOLFOX over CAPOX
CitationAlexander PG, Roseweir AK, Pennel KAF, van Wyk HC, Powell A, McMillan DC, et al. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. Br J Cancer. 2020.
JournalBritish Journal of Cancer
- Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
- Authors: Roseweir AK, Park JH, Hoorn ST, Powell AG, Aherne S, Roxburgh CS, McMillan DC, Horgan PG, Ryan E, Sheahan K, Vermeulen L, Paul J, Harkin A, Graham J, Sansom O, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J
- Issue date: 2020 Oct
- Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.
- Authors: Park JH, McMillan DC, Powell AG, Richards CH, Horgan PG, Edwards J, Roxburgh CS
- Issue date: 2015 Feb 15
- The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
- Authors: van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ
- Issue date: 2016 Jul 12
- Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer.
- Authors: Hwang HW, Kim JY, Lee SE, Choi YS, Hong SH, Lee TJ, Kim MK, Park ES, Hong SA
- Issue date: 2020 Sep
- Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
- Authors: Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A
- Issue date: 2020 Apr 1